I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ESMO 2020
Roche and Genentech at

ESMO 2020

September 19 - September 21
Madrid, Spain
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Highlights
All content will be available on MEDICALLY soon. All of our Roche-sponsored satellite symposia will be available on MEDICALLY on 19th October. In the meantime you can find the materials on esmo.org
09:00 AM
Duration 5mins Virtual
Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative locally advanced/metastatic breast cancer (LA/MBC): Primary results from Cohort B of the IPATunity130 randomised phase 3 trial
Turner N
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 5mins Virtual
IMpower133 characterisation of long term survivors treated first line with chemotherapy atezolizumab▼ in extensive stage small cell lung cancer
Liu S
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 5mins Virtual
End-of-study analysis from JACOB: a phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC)
Tabernero J
Oncology | Gastrointestinal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 5mins Virtual
Pan-cancer analysis of homologous recombination (HR)-associated alterations (alts) and genome-wide loss of heterozygosity (gLOH)
Westphalen B
Oncology | Foundation Medicine

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 5mins Virtual
Patient (pt) preference for the pertuzumab–trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
O'Shaughnessy J
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:00 PM
Duration 30mins Virtual
The integration of technology into patient management: lessons learned from the COVID-19 pandemic
Paolo Marchetti
Oncology

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:20 PM
Duration 12mins Virtual
Primary results from IMpassion131, a double-blind placebo-controlled randomised phase 3 trial of 1st-line paclitaxel ± atezolizumab▼ for unresectable locally advanced/metastatic triple-negative breast cancer
D Miles
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 30mins Virtual
The impact of a digital tumor board solution on multidisciplinary meetings
Richard Hammer
Oncology

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:32 PM
Duration 12mins Virtual
IMpassion130: Final OS analysis from the pivotal Phase III study of atezolizumab▼ + nab-paclitaxel vs placebo + nab-paclitaxel in patients with previously untreated locally advanced or metastatic triple-negative breast cancer
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:16 PM
Duration 12mins Virtual
Patient-reported outcomes from IMvigor130: a global, randomised, partially blinded Phase III study of atezolizumab + platinum-based chemotherapy vs placebo + platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
Bamias A
Oncology | Urogenital Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:02 PM
Duration 12mins Virtual
IPATential150: efficacy and safety from the Phase III study of ipatasertib▼ plus abiraterone vs placebo plus abiraterone in metastatic castration-resistant prostate cancer
De Bono J
Oncology | Urogenital Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:30 PM
Duration 12mins Virtual
IMpassion031: Results from a Phase III study of neoadjuvant atezolizumab▼ + chemotherapy in early triple-negative breast cancer (TNBC)
Harbeck N
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:38 PM
Duration 12mins Virtual
Intracranial efficacy of entrectinib▼ in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
John T
Oncology | Solid Tumours

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:20 PM
Duration 12mins Virtual
Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase 3 trial of bevacizumab▼ (bev)-containing therapy ∓atezolizumab▼ (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
Moore K
Oncology | Ovarian Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

Sign up or login to unlock the full suite of MEDICALLY features
ESMO 2020 In-depth Report: Breast Cancer
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
ESMO 2020 In-depth Report: Gastrointestinal cancers
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
ESMO 2020 In-depth Report: Genitourinary cancers
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
ESMO 2020 In-depth Report: Lung cancer
Springer Healthcare
Open asset

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.